Sysmex (OTCMKTS:SSMXY) Issues FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.580-0.580 for the period. The company issued revenue guidance of $3.3 billion-$3.3 billion.

Sysmex Stock Performance

Sysmex stock traded down $0.06 during midday trading on Wednesday, reaching $18.22. The stock had a trading volume of 50,884 shares, compared to its average volume of 84,987. The company has a quick ratio of 2.42, a current ratio of 3.19 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $11.47 billion, a PE ratio of 36.91 and a beta of 0.90. Sysmex has a 12 month low of $14.38 and a 12 month high of $28.58. The firm’s 50-day moving average price is $18.92 and its 200 day moving average price is $19.02.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter. As a group, research analysts predict that Sysmex will post 0.57 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.